BidaskClub lowered shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) from a buy rating to a hold rating in a research report sent to investors on Tuesday.

Several other research firms also recently commented on BCRX. JMP Securities upped their target price on BioCryst Pharmaceuticals from $12.00 to $16.00 and gave the company an outperform rating in a research report on Wednesday, September 5th. HC Wainwright reaffirmed a buy rating and issued a $13.00 target price on shares of BioCryst Pharmaceuticals in a research report on Monday, August 13th. They noted that the move was a valuation call. Jefferies Financial Group reiterated a buy rating and issued a $8.50 price target on shares of BioCryst Pharmaceuticals in a research note on Thursday, August 9th. Bank of America upgraded BioCryst Pharmaceuticals from an underperform rating to a neutral rating in a research note on Tuesday, July 17th. Finally, Zacks Investment Research upgraded BioCryst Pharmaceuticals from a sell rating to a hold rating in a research note on Tuesday, July 10th. Four equities research analysts have rated the stock with a hold rating, five have given a buy rating and two have given a strong buy rating to the company’s stock. BioCryst Pharmaceuticals presently has a consensus rating of Buy and a consensus price target of $9.89.

BioCryst Pharmaceuticals stock opened at $7.01 on Tuesday. BioCryst Pharmaceuticals has a 12 month low of $4.12 and a 12 month high of $8.13. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.25 and a current ratio of 1.25. The company has a market capitalization of $834.59 million, a PE ratio of -8.99 and a beta of 1.64.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Tuesday, August 7th. The biotechnology company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.05. BioCryst Pharmaceuticals had a negative return on equity of 107.85% and a negative net margin of 270.95%. The company had revenue of $12.49 million for the quarter, compared to the consensus estimate of $3.80 million. On average, analysts anticipate that BioCryst Pharmaceuticals will post -0.86 EPS for the current year.

In related news, insider Thomas R. Staab II sold 9,850 shares of the business’s stock in a transaction that occurred on Wednesday, October 3rd. The stock was sold at an average price of $7.24, for a total value of $71,314.00. Following the completion of the sale, the insider now directly owns 140,633 shares in the company, valued at $1,018,182.92. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CMO William P. Sheridan sold 62,500 shares of the business’s stock in a transaction that occurred on Thursday, August 9th. The shares were sold at an average price of $7.03, for a total value of $439,375.00. Following the completion of the sale, the chief marketing officer now owns 85,713 shares of the company’s stock, valued at $602,562.39. The disclosure for this sale can be found here. Insiders own 5.21% of the company’s stock.

Hedge funds have recently modified their holdings of the stock. Janus Henderson Group PLC boosted its stake in shares of BioCryst Pharmaceuticals by 45.0% in the second quarter. Janus Henderson Group PLC now owns 11,096,183 shares of the biotechnology company’s stock valued at $63,581,000 after buying an additional 3,441,498 shares during the period. Allianz Asset Management GmbH lifted its stake in BioCryst Pharmaceuticals by 40.5% during the first quarter. Allianz Asset Management GmbH now owns 231,761 shares of the biotechnology company’s stock worth $1,105,000 after purchasing an additional 66,783 shares during the last quarter. Spark Investment Management LLC bought a new stake in BioCryst Pharmaceuticals during the second quarter worth $344,000. State of Wisconsin Investment Board lifted its stake in BioCryst Pharmaceuticals by 79.1% during the second quarter. State of Wisconsin Investment Board now owns 100,300 shares of the biotechnology company’s stock worth $575,000 after purchasing an additional 44,300 shares during the last quarter. Finally, Paloma Partners Management Co bought a new stake in BioCryst Pharmaceuticals during the second quarter worth $174,000. Institutional investors and hedge funds own 80.23% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan.

Recommended Story: How Buying a Call Option Works

Analyst Recommendations for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.